Evidence supporting the use of: Marine fat
For the health condition: Multiple Sclerosis

Links: Go back one page, Tool main page, Ingredients list, Health conditions list, Body systems list

Synopsis

Source of validity: Scientific
Rating (out of 5): 2

Marine fat, particularly in the form of fish oil rich in omega-3 polyunsaturated fatty acids (PUFAs) such as eicosapentaenoic acid (EPA) and docosahexaenoic acid (DHA), has been investigated for its potential role in the management of Multiple Sclerosis (MS). The scientific rationale is based on the anti-inflammatory properties of omega-3 PUFAs, which may help modulate immune responses implicated in MS pathology. Some observational studies have shown that higher intake of marine-derived omega-3s correlates with a lower risk of developing MS or with milder disease progression. However, randomized controlled trials (RCTs) have yielded mixed results. A 2012 Cochrane review concluded that supplementation with omega-3 fatty acids did not provide significant benefit over placebo in preventing relapses or disability progression in MS patients. More recent studies continue to show no clear clinical benefit, although they confirm the safety of supplementation. Thus, while there is a scientific basis for investigating marine fat in MS, the current body of clinical evidence does not strongly support its use as a therapeutic intervention. Ongoing research may clarify any potential benefits, but at present, marine fat should not be considered a primary or standalone treatment for MS.

More about Marine fat
More about Multiple Sclerosis

Products containing Marine fat

We currently have no products on Vitabase that contain this ingredient.